Exact Mass: 397.2187716

CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2304 INTERNAL_ID 2304; CONFIDENCE Reference Standard (Level 1)

Heliosupine

7-Angelyl-9-echimidinylheliotridine

Drotaverine

(1Z)-1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline

Drotaverine (INN, also known as drotaverin) is an antispasmodic drug, structurally related to papaverine. Drotaverine is a selective inhibitor of phosphodiesterase 4, and has no anticholinergic effects. Drotaverine has been shown to possess dose-dependant analgesic effects in animal models. One small study has shown drotaverine to be eliminated mainly non-renally. A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AD - Papaverine and derivatives C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

1-(3,4-Diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline

1-[(3,4-diethoxyphenyl)methyl]-6,7-diethoxy-3,4-dihydroisoquinoline

Comfrey

7-({[2,3-dihydroxy-2-(propan-2-yl)butanoyl]oxy}methyl)-1-[(2-methylbut-2-enoyl)oxy]-1,2,3,4,5,7a-hexahydropyrrolizin-4-ium-4-olate

4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine

1-[4-(2H-1,2,3,4-tetrazol-5-yl)butyl]-4-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}piperidine

C25H27N5 (397.22663420000003)

Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate

N2-{1-[2-(methoxycarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl}-N3-propyloxirane-2,3-dicarboximidate

C19H31N3O6 (397.2212746)

N-Acetyl-9-aminominocycline, (4R)-

6-[3-[1-(Dimethylamino)-2-methylpentan-3-yl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

AT-56

4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine

C25H27N5 (397.22663420000003)

dihydroprecondylocarpine acetate

C23H29N2O4+ (397.2127214)

An organic cation which is an intermediate in the biosynthetic pathway leading to the synthesis of the monoterpenoid indole alkaloids, catharanthine and tabersonine.

Heliosupin

(1S,7aR)-7-[({(2S)-2,3-dihydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoyl}oxy)methyl]-2,3,5,7a-tetrahydro-1H-pyrrolo[1,2-a]pyrrol-1-yl (2Z)-2-methylbut-2-enoate

Heliosupine is an azabicycloalkane compound having angelyloxy and echimidinyloxymethyl substituents attached to the ring system. It is an azabicycloalkane, a diester and a 2-methylbut-2-enoic acid. It is functionally related to an angelic acid and an isocrotonic acid. Heliosupine is a natural product found in Cynoglossum australe, Paracaryum rugulosum, and other organisms with data available. See also: Comfrey Leaf (part of); Comfrey Root (part of). An azabicycloalkane compound having angelyloxy and echimidinyloxymethyl substituents attached to the ring system.

MMV026356

C20H27N7O2 (397.2226122)

PC(9:0/0:0)

3,5,9-Trioxa-4-phosphaoctadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (R)-

PC(9:0/0:0)[U]

3,5,9-Trioxa-4-phosphaoctadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide

PC(0:0/9:0)[U]

3,5,8-Trioxa-4-phosphaheptadecan-1-aminium, 4-hydroxy-7-(hydroxymethyl)-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide

PE(12:0/0:0)

Dodecanoic acid, 3-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-2-hydroxypropyl ester, (R)-

C21H35NO4S (397.2286670000001)

(±)14(15)-EET-SI

N-(methylsulfonyl)-13-(3-pentyloxiranyl)-5Z,8Z,11Z-tridecatrienamide

Drotaverin

(1Z)-1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline

A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AD - Papaverine and derivatives C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

LPC 9:0

1-nonanoyl-sn-glycero-3-phosphocholine

LPE 12:0

Dodecanoic acid, 3-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-2-hydroxypropyl ester, (R)-

CA-074 methyl ester

Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate

C19H31N3O6 (397.2212746)

Diethylamino hydroxybenzoyl hexyl benzoate

(-)-Butaclamol Hydrochloride

C25H32ClNO (397.2172292)

(+)-Butaclamol Hydrochloride

C25H32ClNO (397.2172292)

4-(2-(BENZYL(METHYL)AMINO)ETHYL)-1,2-PHENYLENE BIS(2-METHYLPROPANOATE)

manganese neodecanoate

C20H38MnO4 (397.2150408)

Cc-223

C21H27N5O3 (397.2113792)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2. Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.

(2S)-1-[(2S)-3-methyl-1-oxo-2-[[oxo-[(2S,3S)-3-[oxo(propylamino)methyl]-2-oxiranyl]methyl]amino]pentyl]-2-pyrrolidinecarboxylic acid methyl ester

C19H31N3O6 (397.2212746)

(1r,7ar)-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-4-hydroxy-3-methylbut-2-enoate

(1r,7ar)-7-({[(2s)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate

(1s,12s,14s,15e)-15-ethylidene-13-(hydroxymethyl)-6-methoxy-13-(methoxycarbonyl)-17-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-17-ium

[C23H29N2O4]+ (397.2127214)

(1r,7ar)-7-({[(2r)-2,3-dihydroxy-2-isopropylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-4-hydroxy-3-methylbut-2-enoate

(7r,7ar)-1-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-7-{[(2e)-2-methylbut-2-enoyl]oxy}-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate